Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33149112.
- Also identified by DOI 10.1038/s41467-020-19204-y and PMC identifier 7642358.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The coronavirus SARS-CoV-2 is the cause of the ongoing COVID-19 pandemic. Therapeutic neutralizing antibodies constitute a key short-to-medium term approach to tackle COVID-19. However, traditional antibody production is hampered by long development times and costly production. Here, we report the rapid isolation and characterization of nanobodies from a synthetic library, known as sybodies (Sb), that target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Several binders with low nanomolar affinities and efficient neutralization activity were identified of which Sb23 displayed high affinity and neutralized pseudovirus with an IC<sub>50</sub> of 0.6 µg/ml. A cryo-EM structure of the spike bound to Sb23 showed that Sb23 binds competitively in the ACE2 binding site. Furthermore, the cryo-EM reconstruction revealed an unusual conformation of the spike where two RBDs are in the 'up' ACE2-binding conformation. The combined approach represents an alternative, fast workflow to select binders with neutralizing activity against newly emerging viruses.
Medical subject headings
- Betacoronavirus
- Coronavirus Infections
- Pandemics
- Peptidyl-Dipeptidase A
- Pneumonia, Viral
- Single-Domain Antibodies
- Spike Glycoprotein, Coronavirus